𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

✍ Scribed by Richard Furie; Michelle Petri; Omid Zamani; Ricard Cervera; Daniel J. Wallace; Dana Tegzová; Jorge Sanchez-Guerrero; Andreas Schwarting; Joan T. Merrill; W. Winn Chatham; William Stohl; Ellen M. Ginzler; Douglas R. Hough; Z. John Zhong; William Freimuth; Ronald F. van Vollenhoven; BLISS-76 Study Group

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
684 KB
Volume
63
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II, randomized, double-blind, pl
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus
✍ Wallace, Daniel J. ;Stohl, William ;Furie, Richard A. ;Lisse, Jeffrey R. ;McKay, 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 372 KB 👁 2 views

## Abstract ## Objective To assess the safety, tolerability, biologic activity, and efficacy of belimumab in combination with standard of care therapy (SOC) in patients with active systemic lupus erythematosus (SLE). ## Methods Patients with a Safety of Estrogens in Lupus Erythematosus: National

LJP 394 for the prevention of renal flar
LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: Results from a randomized, double-blind, placebo-controlled study
✍ Donato Alarcón-Segovia; James A. Tumlin; Richard A. Furie; James D. McKay; Mario 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB 👁 2 views

## Abstract ## Objective To determine whether LJP 394 delays or prevents renal flare in patients with systemic lupus erythematosus (SLE) and a history of renal disease. ## Methods In a 76‐week, double‐blind, placebo‐controlled study, 230 SLE patients were randomized to receive 16 weekly doses of